View All Upcoming Sponsored Webinars
Recorded September 24, 2015
The success rate of potential novel anti-cancer therapeutics has historically been low, hovering around 5%, and is attributed, at least in part, to the widespread use of readily available but imperfect models at the preclinical phase. We now appreciate that tumor environment and location are of critical importance to the growth, progression and therapeutic response of cancer. For these reasons, the translational predictivity of preclinical efficacy studies is enhanced when cancer cells of a particular tissue origin are assayed following implantation at the corresponding orthotopic site, as opposed to as subcutaneous grafts. Unfortunately, the relative inaccessibility of many organs (e.g. pancreas, brain, bone, etc.), makes delivery of cancer cells to these sites technically challenging and obfuscates subsequent monitoring of tumor growth kinetics. Ultimately, these limitations have stifled the development of efficacious therapeutic agents for cancers of these origins. The use of patient-derived xenograft lines, transduced bioluminescent reporter proteins, and expertise in delivering cancer cells to orthotopic sites has revolutionized our ability to assay the efficacy of potential anti-cancer agents. We will discuss the current generation of specialized preclinical oncology models that more closely recapitulate the clinical condition and offer enhanced predictive potential for development of novel therapies.
Benjamin G. Cuiffo, PhD.
Principal Scientist, Oncology
Dr. Cuiffo joined Biomodels in 2015 after completing his postdoctoral studies at Beth Israel Deaconess Medical Center and Harvard Medical School, where he was an American Cancer Society Fellow. His postdoctoral work centered upon elucidating the molecular mechanisms of tumor metastasis in preclinical in vitro and in vivo models. Dr. Cuiffo brings additional expertise in the biology of tumor- initiating (cancer stem cells) and invasive phenotypes, oncogenic signaling pathways, and noncoding RNAs in cancer. He received his Ph.D. in Molecular and Cell Biology from Brandeis University in 2010, where he developed novel strategies to target the RAS oncogene in animal models of leukemia. As the Lead Oncology Scientist at Biomodels, Dr Cuiffo will collaborate with clients to design and execute clinically translational preclinical Oncology studies.
250 First Avenue Suite 300Needham, MA 02494P: 781.972.5400F: 781.972.5425E: firstname.lastname@example.org
biological therapeutic productsbiomarkers & diagnosticsbiopharma strategybioprocess & manufacturingchemistryclinical trials & translational medicinedrug & device safety
drug discovery & developmentdrug targetsgenomicshealthcareit & informaticstechnology & tools for life sciencetherapeutic indications
conferencesReports & Market Researchbarnett educational servicesHealthtech PublishingKnowledge Foundation professional services
executive teamtestimonialschi timelinemailing listcareers